These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068 [TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic Wernicke's Encephalopathy Followed by Neuromyelitis Optica Spectrum Disorders: A Case Report. Zhang D; Yang X; Zhang Z; Zhao W; Duan P; Du G Neurol India; 2019; 67(6):1562-1564. PubMed ID: 31857564 [No Abstract] [Full Text] [Related]
6. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia. Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527 [TBL] [Abstract][Full Text] [Related]
8. Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Ringelstein M; Metz I; Ruprecht K; Koch A; Rappold J; Ingwersen J; Mathys C; Jarius S; Brück W; Hartung HP; Paul F; Aktas O; Mult Scler; 2014 Jun; 20(7):882-8. PubMed ID: 24192218 [TBL] [Abstract][Full Text] [Related]
9. Aquaporin-4 antibody in neuromyelitis optica: re-testing study in a large population from China. Long Y; Liang J; Zhong R; Wu L; Qiu W; Lin S; Gao C; Chen X; Zheng X; Yang N; Gao M; Wang Z Int J Neurosci; 2017 Sep; 127(9):790-799. PubMed ID: 27838939 [TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea. Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965 [TBL] [Abstract][Full Text] [Related]
11. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963 [TBL] [Abstract][Full Text] [Related]
12. Overcoming the challenges in diagnosis of AQP4-IgG positive neuromyelitis optica spectrum disorders in resource poor settings using an indigenized and cost effective cell based assay. Pandit L; Malli C; D'Cunha A; Sudhir A J Neuroimmunol; 2021 Nov; 360():577706. PubMed ID: 34507014 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Popescu BF; Guo Y; Jentoft ME; Parisi JE; Lennon VA; Pittock SJ; Weinshenker BG; Wingerchuk DM; Giannini C; Metz I; Brück W; Shuster EA; Carter J; Boyd CD; Clardy SL; Cohen BA; Lucchinetti CF Neurology; 2015 Jan; 84(2):148-58. PubMed ID: 25503621 [TBL] [Abstract][Full Text] [Related]
15. Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder. Park JH; Hwang J; Min JH; Kim BJ; Kang ES; Lee KH J Neurol Sci; 2015 Jan; 348(1-2):132-5. PubMed ID: 25500159 [TBL] [Abstract][Full Text] [Related]